Keyphrases
Cost-effectiveness
100%
Non-ST-segment Elevation Acute Coronary Syndrome (NSTE-ACS)
100%
Clopidogrel
100%
Ticagrelor
100%
Quality-adjusted Life Years
50%
ST-elevation Myocardial Infarction (STEMI)
40%
Popular
40%
Cost Savings
30%
Elderly Patients
20%
Clinical Outcomes
20%
Alternative Basis
20%
Negative Effects
10%
Health Status
10%
Clinical Quality
10%
Markov Model
10%
First Year
10%
Decision Tree
10%
Bleeding Risk
10%
Tree-based
10%
High Bleeding Risk
10%
Overall Cost
10%
Equal Distribution
10%
Thrombotic Events
10%
Outcome Quality
10%
Clinical Costs
10%
Long-term Costs
10%
Systems Perspective
10%
Utility Data
10%
Event Rate
10%
Dutch Healthcare System
10%
Outcome Costs
10%
Lifetime Projection
10%
INIS
patients
100%
coronaries
100%
cost
100%
elevation
100%
risks
22%
comparative evaluations
22%
data
11%
distribution
11%
utilities
11%
markov process
11%
lifetime
11%
decision tree analysis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Coronary Syndrome
100%
Clopidogrel
100%
Ticagrelor
100%
Non ST Segment Elevation Myocardial Infarction
40%
Base
20%
Bleeding
10%
Health Status
10%
Biochemistry, Genetics and Molecular Biology
Clopidogrel
100%
ST Elevation
100%
Quality Adjusted Life Year
50%
Lifespan
10%
Health Status
10%
Decision Trees
10%